Maria Escolar, MD, on Treating Krabbe Disease With Investigational Gene Therapy FBX-101
The chief medical officer of Forge Biologics discussed updated data from the phase 1/2 RESKUE clinical trial that she presented at ASGCT’s 2023 conference.
Maria Escolar, MD, on Combining HSCT With Gene Therapy in Krabbe Disease
The chief medical officer of Forge Biologics discussed the potential advantages of the investigational combination therapy approach.
Maria Escolar, MD, on Addressing Unmet Needs in Krabbe Disease With Gene Therapy
The chief medical officer of Forge Biologics discussed clinical data presented at ESGCT.
